Arcus Biosciences, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company whose common stock trades on the New York Stock Exchange under RCUS. Form 8-K reports include quarterly and annual results furnished with pipeline updates, clinical program disclosures, collaboration updates, executive changes and material agreements tied to the company’s financing and development activities.
Arcus filings also cover capital structure and governance matters, including a completed common stock offering, amendments to a loan and security agreement, annual proxy materials, board and executive compensation disclosures, equity incentive matters and stockholder meeting proposals. The filing record reflects risk and operating disclosures connected to drug development, clinical studies, regulatory pathways, collaborations and funding needs.
Arcus Biosciences (RCUS) reported an insider transaction by its Chief Financial Officer. On 10/28/2025, the CFO sold 5,000 shares of common stock at $20 per share, coded as an open market sale (S).
Following the transaction, the officer beneficially owns 92,138 shares, held directly. The filing notes the sales were made under a Rule 10b5-1 trading plan adopted on March 7, 2023, which pre-schedules trades.
Arcus Biosciences (RCUS): A shareholder filed an amended Form 144 to sell up to 5,000 shares of common stock. The filing lists an aggregate market value of $100,000 and an approximate sale date of 10/28/2025. The planned sales are through Merrill Lynch on the NYSE.
The filing notes 106,430,976 shares outstanding; this is a baseline figure, not the amount being sold. The shares to be sold were acquired on 12/15/2023 via equity compensation.
Arcus Biosciences (RCUS) filed a Form 144 for a proposed sale of 5,000 shares of common stock through Merrill Lynch on the NYSE, with an aggregate market value of $100,000 and an approximate sale date of 10/28/2025.
The seller acquired 5,000 shares on 12/15/2023 via equity compensation. Shares outstanding were 106,430,976. Form 144 is a notice of intent to sell restricted or control securities under Rule 144.
Arcus Biosciences (RCUS): Notice of proposed sale under Form 144. A security holder filed to sell 100,000 shares of Class A common stock through Goldman Sachs & Co. LLC on the NYSE, with an aggregate market value of $1,988,000. The approximate sale date is 10/28/2025.
The shares were originally acquired from the issuer in a private transaction on 05/29/2015, with payment on the same date. Shares outstanding were 106,430,976, providing scale context for the proposed sale.
Arcus Biosciences (RCUS) reported Q3 2025 results. Total revenues were $26 million, down from $48 million a year ago, driven by collaboration revenue timing. The company posted a net loss of $135 million versus a $92 million loss last year as research and development expense rose to $141 million and general and administrative expense was $27 million.
For the nine months, revenues were $214 million versus $232 million. A June modification to the Gilead collaboration following termination of etrumadenant rights led to a $143 million cumulative catch-up to revenue, which reduced basic and diluted net loss per share by $1.38 in the period.
Liquidity remained strong with $841 million in cash, cash equivalents and marketable securities as of September 30, 2025; management believes this funds operations for at least twelve months. Operating cash flow used was $362 million year-to-date. Deferred revenue declined to $105 million from $319 million at year-end, reflecting revenue recognition progress. Long-term debt was $98 million under the Hercules facility. Equity financing included a $150 million underwritten offering at $11.00 per share and $8 million via an at-the-market program. In October 2025, Taiho exercised its option for casdatifan for a $15 million payment.
Arcus Biosciences, Inc. furnished a current report to share that it has issued a press release announcing its financial results for the nine months ended September 30, 2025. The company states that the full text of this results press release is provided as Exhibit 99.1 and is incorporated by reference. The information about these results is furnished under Item 2.02 of the report, meaning it is not treated as filed for liability purposes under the Exchange Act unless specifically incorporated into another filing.
Arcus Biosciences (RCUS) reported first overall survival results from Arm A1 of its Phase 2 EDGE-Gastric study in advanced gastric, GEJ, or esophageal adenocarcinoma. At data cutoff on March 3, 2025, all 41 treated patients were evaluated with a median follow-up of 26.4 months.
The regimen of domvanalimab plus zimberelimab and chemotherapy showed median overall survival of 26.7 months (90% CI: 18.4, NE) in the overall population and 26.7 months (90% CI: 19.5, NE) in PD‑L1 positive patients. In PD‑L1 high patients, median overall survival was not estimable (90% CI: 17.4, NE). The 24‑month overall survival rate was 50.2% (90% CI: 36.3, 62.6). Median progression‑free survival was 12.9 months (90% CI: 9.8, 14.6), and confirmed objective response rate was 59% (24/41; 90% CI: 45%, 72%).
No unexpected safety signals were observed. The safety profile was generally well tolerated and consistent with anti‑PD‑1 plus chemotherapy. Immune‑mediated TEAEs occurred in 9 patients (22%), and infusion‑related reactions in 3 patients (7%).
Insider transactions by Arcus Biosciences (RCUS): The company's Chief Operating Officer exercised stock options and sold a total of 50,292 shares across two dates, 10/06/2025 and 10/08/2025. The exercises used options with a $1.2276 exercise price, adding 50,292 underlying shares to the reporting pool. Sales were executed at weighted-average prices of $14.5441 and $15.0458, and the filings state these transactions were made pursuant to a Rule 10b5-1 trading plan. Following the transactions the reporting person beneficially owned 214,232 shares, which includes 863 shares bought via the employee stock purchase plan on 05/30/2025. The options exercised were fully vested and exercisable, with expiration dates noted as 03/14/2027.
Arcus Biosciences, Inc. filed a Form 144 reporting a proposed sale of 100,583 shares of common stock through J.P. Morgan Securities LLC on 10/06/2025. The filing shows the shares were acquired and paid for on 10/06/2025 via a stock option exercise with payment in cash. The aggregate market value listed for the shares to be sold is 1,342,783 and the total shares outstanding are 106,430,976, which implies the block represents roughly 0.095% of outstanding shares. No other sales in the past three months were reported and no seller name is disclosed in the public sections of the form.
Arcus Biosciences reported updated Phase 1/1b ARC-20 monotherapy data for casdatifan in metastatic clear cell renal cell carcinoma and outlined new immunology and inflammation programs. Across four dosing cohorts (total n=121 in the pooled analysis), pooled median progression-free survival was 12.2 months, with a 12‑month PFS rate of 50% and a confirmed objective response rate of 31%. The pooled disease control rate was 81%, and median time to response was about three months.
In the safety-evaluable population (n=127), 31% of patients experienced serious treatment-emergent adverse events, while Grade ≥3 treatment-emergent events related to casdatifan occurred in 49% of patients, most commonly anemia and hypoxia. Arcus stated that no unexpected safety signals were observed and that casdatifan had an acceptable and manageable safety profile. The company also highlighted several advanced discovery and preclinical programs in immunology and inflammation, and expects to initiate one or more clinical studies from these programs in 2026.